N-of-1 Trial
An N-of-1 trial is a single-patient randomized controlled trial in which a patient alternates between treatment A and treatment B (or active drug and placebo) in repeated, randomized cross-over periods. Developed systematically in the 1990s–2010s by Kravitz, Duan, and Vohra, N-of-1 trials enable personalized medicine by determining which treatment works best for that specific individual, avoiding the assumption that population-average effects apply to all patients. They are ideal for chronic conditions with variable outcomes and heterogeneous treatment response.
Avota reģistrs
Atsauces kopētas tieši no metodes avota reģistra. Tās nenozīmē nekādu apgalvojumu līmeņa verifikāciju.
- Gabler, N. B., Duan, N., Vohra, S., & Kravitz, R. L. (2011). N-of-1 trials in the medical literature: a systematic review. Medical Care, 49(8), 761–768. · DOI 10.1097/mlr.0b013e318215d90d
- Kravitz, R. L., Duan, N., & Eslick, I. (2010). Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. The Milbank Quarterly, 88(4), 503–520. · URL
- Vohra, S., Shamseer, L., Sampson, M., Barrowman, N., Yap, B., Uleryk, E., ... & Moher, D. (2015). CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. BMJ Open, 5(7), e007838. · DOI 10.1136/bmj.h1793
Kurēti apgalvojumi
Apgalvojumi saglabāti pierādījumu reģistrā, katram ar savu novērtējumu.
Šis skatījums neizgudro apgalvojumu novērtējumu, ja reģistrā tā nav.
Saistītās metodes
Ģenerēts no metodes grafika un parādīts kā mašīnas ieteiktas attiecības — netiek izvirzīts neviens pierādījumu apgalvojums.